Screener / SEC EDGAR /CIK 0001579428 /10-K filed Feb 23, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Axsome Therapeutics, Inc. AXSM

Compare with peers Embed
FY2025 at a glance

Sales up 65.5%, free cash flow up to -$93.9M

XBRL, from each 10-K
RevenueStatements
$638.5M from $385.7M in FY2024
FY2016FY2025
Net incomeStatements
-$183.2M from -$287.2M in FY2024
FY2016FY2025
Free cash flowStatements
-$93.9M from -$128.7M in FY2024
FY2016FY2025
EPS (diluted)Statements
$-3.68 from $-5.99 in FY2024
FY2016FY2025
Operating marginStatements
-26.1% from -72.7% in FY2024
FY2016FY2025
Total debtStatements
$187.7M from $180.7M in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (34)
EPS (ttm)
-3.03
Sales (ttm)
865.3M
Net income (ttm)
-157.3M
Sales growth
+65.5%
EPS growth
-
Sales Q/Q
+51.9%
Free cash flow
-82.6M
Gross margin
-
Oper. margin
-17.5%
Net margin
-18.2%
FCF margin
-9.5%
R&D / sales
28.7%
Dividend
-
Debt/Eq
1.78
Curr. ratio
1.42
Cash
313.9M
Op. cash flow (ttm)
-81.8M
EBITDA
-166.3M
EBITDA margin
-26.0%
Net debt
-125.8M
Quick ratio
1.37
FCF after stock pay
-187.6M
Goodwill / assets
1.7%
Stock pay / sales
14.7%
Shares out.
52.6M
Shares Y/Y
+3.8%
Book / share
2.00
Cash / share
5.97
Sales / share
16.45
Asset turnover
1.05
Days sales out.
128
Sales 3Y CAGR
+134%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2020 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 638.5M Net income -183.2M
FY2020 revenue 0 · OperatingIncomeLoss+CostsAndExpenses, 0000950170-23-004728 FY2020 net income -102.9M · NetIncomeLoss, 0000950170-23-004728 0 FY2020 FY2021 revenue 0 · OperatingIncomeLoss+CostsAndExpenses, 0000950170-24-019118 FY2021 net income -130.4M · NetIncomeLoss, 0000950170-24-019118 0 FY2021 FY2022 revenue 50.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-25-022457 FY2022 net income -187.1M · NetIncomeLoss, 0000950170-25-022457 50.0M FY2022 FY2023 revenue 270.6M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-064267 FY2023 net income -239.2M · NetIncomeLoss, 0001193125-26-064267 270.6M FY2023 FY2024 revenue 385.7M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-064267 FY2024 net income -287.2M · NetIncomeLoss, 0001193125-26-064267 385.7M FY2024 FY2025 revenue 638.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-064267 FY2025 net income -183.2M · NetIncomeLoss, 0001193125-26-064267 638.5M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing.

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share -10.3% a year FY2020 $3.06 to FY2025 $1.77, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$3.68$1.77-$1.89
Dec 31, 2024 -$5.99$1.19-$2.69
Dec 31, 2023 -$5.27$4.20-$3.21
Dec 31, 2022 -$4.60$2.69-$2.88
Dec 31, 2021 -$3.47$0.42-$2.89
Dec 31, 2020 -$2.77$3.06-$2.11
Dec 31, 2019 ---
Dec 31, 2018 ---
Dec 31, 2017 ---
Dec 31, 2016 ---
Dec 31, 2015 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $589.0M
  • − All liabilities $601.5M
  • = Net current asset value -$12.5M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $88.3M
  • − Goodwill $12.0M
  • − Other intangible assets $40.5M
  • = Tangible book value $35.7M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

AXSM against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+65.5%11th of 155 · median +10.5%
Net margin
-4.1%15.3%
-18.2%127th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-149.2%144th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
-9.5%122nd of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
1.7894th of 108 · median 0.69
AXSM and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
AXSM Axsome Therapeutics, Inc.$865.3M +65.5%--18.2%-149.2%-9.5%1.78
TGTX TG Therapeutics, Inc.$897.8M +87.3%82.7%11.8%18.5%9.5%1.30
INSP Inspire Medical Systems, Inc.$880.9M +13.6%86.2%11.4%12.2%11.1%-
SUPN Supernus, Inc.$865.1M +8.6%87.6%-5.1%-4.1%10.1%-
IRTC iRhythm Holdings, Inc.$854.0M +26.2%72.3%-4.5%-21.8%0.9%-
RGEN Repligen Corp$805.6M +16.4%53.5%-1.5%-0.6%13.2%0.27
All 162 companies in the group

Where the $638.5M of revenue came from

by product, year to Dec 31, 2025

  • Product Sales $633.8M · 99%
  • Royalty and Milestone Revenue $4.7M · 1%

From the segment tables in the 10-K XBRL.

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2022 · 10-K XBRL, year-end balances

Return on equity -207.5% FY2022: -170.8% net income ÷ equity
Net margin -28.7% FY2022: -374.0% profit per $ of sales: -183.2M ÷ 638.5M
Asset turnover 0.93× FY2022: 0.15× sales per $ of assets: 638.5M ÷ 689.8M
Leverage 7.81× FY2022: 3.03× assets per $ of equity: 689.8M ÷ 88.3M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -18.2% vs 6.8%
  • Return on equity below 15%
    -149.2%
  • A profit in 0 of 6 years
Net margin, FY2020 to FY2025: -374.0% to -28.7%

Balance sheet

  • Debt larger than equity
    Debt / equity 1.78 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 1.42
  • More cash than debt
    Net cash $125.8M
Debt / equity at each year end, FY2020 to FY2025: 0.42 to 2.13

Cash and shareholders

  • Free cash flow positive in 0 of 6 years
    −$93.9M last year
  • Share count up over 5 years
    +33.7%
Free cash flow, FY2020 to FY2025: -78.5M to -93.9M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$120.0M of principal due, schedule of Sep 30, 2026

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

AXSM's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue638.5M
FY2016: -FY2017: -FY2018: -FY2019: -FY2020: 0FY2021: 0FY2022: 50.0MFY2023: 270.6MFY2024: 385.7MFY2025: 638.5M FY2017FY2019FY2021FY2023FY2025
Net income-183.2M
FY2016: -27.2MFY2017: -28.9MFY2018: -31.0MFY2019: -68.3MFY2020: -102.9MFY2021: -130.4MFY2022: -187.1MFY2023: -239.2MFY2024: -287.2MFY2025: -183.2M FY2017FY2019FY2021FY2023FY2025
Free cash flow-93.9M
FY2016: -21.4MFY2017: -26.5MFY2018: -30.1MFY2019: -46.4MFY2020: -78.5MFY2021: -108.5MFY2022: -117.2MFY2023: -145.7MFY2024: -128.7MFY2025: -93.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay-187.6M
FY2016: -23.4MFY2017: -28.6MFY2018: -31.8MFY2019: -52.5MFY2020: -93.3MFY2021: -129.3MFY2022: -154.9MFY2023: -208.3MFY2024: -213.9MFY2025: -187.6M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)-3.68
FY2016: -1.42FY2017: -1.27FY2018: -1.15FY2019: -2.01FY2020: -2.77FY2021: -3.47FY2022: -4.60FY2023: -5.27FY2024: -5.99FY2025: -3.68 FY2017FY2019FY2021FY2023FY2025
Diluted shares49.7M
FY2016: -FY2017: -FY2018: -FY2019: -FY2020: 37.2MFY2021: 37.6MFY2022: 40.7MFY2023: 45.4MFY2024: 47.9MFY2025: 49.7M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Product Sales 633.8M99.3% +66.1%
Royalty and Milestone Revenue 4.7M0.7% +17.0%

10-K 0001193125-26-064267, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue----0050.0M270.6M385.7M638.5M
Cost of revenue------5.2M---
R&D21.2M20.0M23.5M53.6M70.2M58.1M57.9M97.9M187.1M183.3M
SG&A6.3M7.2M9.4M13.6M28.9M66.6M159.3M323.1M411.4M570.6M
Operating income-27.5M-27.2M-32.8M-67.2M-99.1M-124.7M-179.8M-231.8M-280.6M-166.8M
Interest expense47K865K772K1.3M2.1M4.6M-9.7M-20.0M-21.6M-15.9M
Pretax income------130.4M-187.1M-238.3M-287.1M-183.7M
Income tax0000000960K85K-530K
Net income-27.2M-28.9M-31.0M-68.3M-102.9M-130.4M-187.1M-239.2M-287.2M-183.2M
EPS (diluted)-1.42-1.27-1.15-2.01-2.77-3.47-4.60-5.27-5.99-3.68
Diluted shares----37.2M37.6M40.7M45.4M47.9M49.7M
Depreciation & amortization20K43K49K37K24K76K263K459K532K503K
EBITDA-27.5M-27.1M-32.8M-67.2M-99.1M-124.6M-179.5M-231.4M-280.0M-166.3M
Operating margin-------359.3%-85.7%-72.7%-26.1%
Net margin-------374.0%-88.4%-74.5%-28.7%
Revenue growth-------+441%+42.5%+65.5%

Balance sheet

From EDGAR

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-21.3M-26.5M-30.1M-46.4M-78.5M-108.2M-116.5M-145.1M-128.4M-93.4M
Capital spending105K10K33K16K46K308K702K582K270K480K
Free cash flow-21.4M-26.5M-30.1M-46.4M-78.5M-108.5M-117.2M-145.7M-128.7M-93.9M
Stock-based pay (added back)2.0M2.1M1.8M6.1M14.8M20.8M37.7M62.6M85.2M93.8M
Free cash flow after stock pay-23.4M-28.6M-31.8M-52.5M-93.3M-129.3M-154.9M-208.3M-213.9M-187.6M
Acquisitions------53.0M---
Debt raised10.0M--20.0M50.0M-----
Debt repaid-278K3.3M7.2M21.7M----332.0M
Investing cash flow-105K-10K-33K-16K-46K-308K-53.7M-582K-270K-480K
Financing cash flow10.0M23.9M10.0M252.4M42.4M11.1M284.6M331.0M57.8M101.5M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)2.0M2.1M1.8M6.1M14.8M20.8M37.7M62.6M85.2M93.8M
Stock-based pay / revenue------75.4%23.1%22.1%14.7%
Operating lease cost----48K1.1M1.2M2.2M2.3M4.7M
Finance lease principal paid--------990K2.1M
Right-of-use assets----1.7M660K420K6.8M5.4M20.9M
Operating lease liabilities----1.8M621K425K8.3M7.9M23.6M
Finance lease liabilities--------4.4M6.8M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AXSM/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.